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CD28/B7 Regulation of Th1 and Th2 Subsets
in the Development of Autoimmune Diabetes
Deborah J. Lenschow,* Kevan C. Herold,† (NOD) mouse. Unlike the R-EAE autoimmune models,
the natural progression of the disease depends on en-Lesley Rhee,* Bina Patel,* Ann Koons,*
dogenous autoantigen exposure over a poorly definedHui-Yu Qin,§ Elaine Fuchs,‡
period of early development. Previously, we observedBhagarith Singh,§ Craig B. Thompson,†‡
that the administration of CTLA-4Ig or anti-B7-2 mAbsand Jeffrey A. Bluestone*
blocked diabetes in the majority of NOD animals*Ben May Institute for Cancer Research
(Lenschow et al., 1995). However, while the CTLA-4IgDepartment of Pathology
treatment prevented the development of diabetes, it hadand The Committee on Immunology
little quantitative effect on the development of insulitis†Committee on Immunology
early in disease progression (Lenschow et al., 1995).and the Department of Medicine
Furthermore, the treatment was efficacious only when‡Committee on Immunology
administered to mice between 5 and 7 weeks of age (D.Howard Hughes Medical Institute
J. L. and J. A. B., unpublished data). Thus, while theand the Department of Molecular Genetics
study of the NOD mice defined an important role forand Cell Biology
the various costimulatory receptors and ligands in theUniversity of Chicago
regulation of the established disease, they did not ad-Chicago, Illinois 60637
dress theeffects of early CD28/B7 blockade,owing to an§Department of Microbiology and Immunology
inability to treat mice at the initiation of the autoimmuneUniversity of Western Ontario
syndrome, prior to B7-1 and CTLA-4 up-regulationLondon, Ontario N6A 5C1
(Lenschow et al., 1996; June et al., 1994). Furthermore,Canada
these reagents have not been able to distinguish be-
tween effects on CD28 versus CTLA-4 interactions.
In this study, we utilized two genetically altered mouseSummary
strains to study the early role of CD28/B7 interactions
in the development and progression of autoimmune dia-CD28 ligation deliversa costimulatory signal important
betes in the NOD mice. First, we bred the NOD mousein T cell activation. This study demonstrates that the
to the gene-disrupted CD28 knockout mouse (CD282/2).disruption of the CD28/B7 pathway early in the non-
Previous studies have shown that T cells from CD28-obese diabetic mouse strain, using CD282/2 and
deficient C57BL/6 mice have decreased proliferative re-CTLA4lg transgenic mice, promoted the development
sponses and produce less interleukin-2 (IL-2) in re-
and progression of spontaneous autoimmune diabe-
sponse to Concanavalin A, anti-CD3, and alloantigen
tes. Functional analyses of T cells isolated from CD28-
stimulation (Shahinian et al., 1993; Green et al., 1994).deficient mice demonstrated that the GAD-specific T
However, these mice can reject allogeneic skin graftscells produced enhanced Th1-type cytokines (IL-2 and
(Kawai et al., 1996) and mount normal anti-lymphocytic
IFNg) and diminished Th2-type cytokine, IL-4. More-
choriomeningitis virus delayed-type hypersensitivity
over, there was a significant decrease in serum levels
(DTH) and cytolytic T cell responses (Shahinian et al.,
of anti-GAD antibodies of the IgG1 isotype consistent
1993), suggesting that some of their cell-mediated im-
with a profound suppression of Th2-type responses mune responses remain intact. Second, we bred NOD
in these animals. Thus, theearly differentiation of naive mice to a recently developed transgenic mouse strain
diabetogenic T cells into the Th2 subset is dependent that expresses murine CTLA-4Ig driven by a skin-spe-
upon CD28 signaling and extends our understanding cific keratin promoter, K14. These animals express
of the importance of Th1/Th2 balance in the regulation 10–30 mg/ml soluble CTLA-4Ig in the serum. Like the
of this spontaneous autoimmune disease. CD282/2 mice, T cells in the CTLA-4Ig Tg mice develop
normally and can mount a potent cell-mediated re-
sponse as assessed by allogeneic skin graft rejection (J.
Introduction Smith, D. J. L., and J. A. B., unpublished data). Together,
these two mouse strains have allowed us to examine
Blockade of CD28/B7 interactions using CTLA-4Ig ther- the early disruption of the CD28/B7 pathway and to
apy has been shown to have significant effects on the determine directly the function of CD28/B7 interactions
experimental course of several autoimmune diseases in the development and progression of this autoimmune
(Perrin et al., 1995; Nakajima et al., 1995; Finck et al., disease.
1994). For instance, in relapsing-experimental autoim- The studies presented in this paper demonstrate that,
mune encephalitis (R-EAE), CTLA-4Ig treatment during in contrast with expectations, both the CTLA-4Ig Tg1
antigen priming blocked the development of clinical dis- NOD mice and the CD282/2 NOD mice displayed a more
ease (Perrin et al., 1995; Cross et al., 1995). Similar re- rapid onset and higher degree of penetrance and sever-
sults were observed in an adoptive transfer model of ity of diabetes compared with their littermate controls.
R-EAE (Perrin at al.,1995) and other autoimmunemodels Further analysis of these animals showed that the dis-
(Finck et al., 1994; Nishikawa et al., 1994). ruption of the CD28/B7 interactions regulated Th1/Th2
We have studied the role of CD28/B7 interactions in a CD41 T cell subset differentiation and contributed to the
exacerbation of the autoimmune disease. These resultsspontaneous model of diabetes, the nonobese diabetic
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Disruption of the CD28/B7 Interactions in CD282/2
NOD Mice Results in an Increased Incidence
of Autoimmune Diabetes
CTLA-4Ig binds to the B7 molecules (B7-1 and B7-2)
and inhibits both CD28 and CTLA-4 interactions. There-
fore, the individual impact that the CD28 and CTLA-4
molecules have on disease progression could not be
distinguished in the previous studies. To examine di-
rectly the role of the CD28 molecule in this disease
process, NOD mice were bred to a CD28-deficient
(CD282/2) mouse strain (Shahinian et al., 1993; Green et
al., 1994). After four generations of backcrossing into
the NOD background, the heterozygous offspring were
intercrossed, generating three different genotypes of
mice (CD281/1 NOD, CD281/2 NOD, and CD282/2 NOD).
By four generations, only a minority (30%) of the CD281/1
(Figure 2, open circles) and CD281/2 (Figure 2, openFigure 1. CTLA-4Ig Tg1 NOD Mice Display an Increased Incidence
of Disease squares) female NOD mice became diabetic, as com-
The CTLA-4Ig Tg mouse was bred onto the NOD mouse as described pared with 70%–80% penetrance in our inbred NOD
in Experimental Procedures. Both the CTLA-4Ig Tg1 NOD mice (n 5 colony.These results were a consequence of the fixation
5) and the Tg2 NOD mice (n 5 12) were monitored for 24 weeks for of three of themajor diabetes susceptibility genes (MHC,
the development of diabetes by measuring weekly blood glucose D3Nds7, and D3Mit5)(D. J. L., L. Wicker, and J. A. B.,
levels.
data not shown), but indicate that other important diabe-
tes susceptibility genes were not yet fixed (Wicker et
al., 1995; Lenschow et al., 1995b). However, despite the
have important implications for the potential clinical use incomplete backcrossing, nearly 70% of the CD282/2
of CD28 antagonists to regulate autoimmunity. NOD mice (Figure 2, solid circles) became diabetic by 24
weeks of age (left). Furthermore, the normally resistant
male mice developed diabetes when bred onto theResults
CD282deficient background (Figure 2, right). Nearly
90% of the male CD282/2 NOD mice were hyperglycemicExpression of Endogenous Murine CTLA-4Ig
by 24 weeks as compared with only 10% of the malePromotes the Development of Autoimmune
CD281/2 NOD mice (Figure 2, right). Therefore, similarDiabetes in NOD Mice
to the results observed in the CTLA-4Ig Tg1 NOD mice,Previous studies had suggested that the inability to in-
the early disruption of the CD28/B7 costimulatory path-
hibit autoimmune insulitis in the NOD mouse by injection
way in the NOD mouse led to an acceleration of the
of CTLA-4Ig might be related to the early onset of spon-
autoimmune process. Furthermore, these results sug-
taneous autoimmunity in the mice. We therefore devel-
gest that the CD28 signaling pathway directly regulates
oped a genetically altered mouse strain in order to intro- the factor(s) that normally control disease development.
duce high levels of circulating murine CTLA-4Ig early in
the disease process. A murine CTLA-4/IgG2aFc hybrid T Cells from the CD282/2 NOD Mice Respond
gene construct was placed behind the keratin promoter to the Autoantigen GAD, but Do Not Respond
(K14) and injected into mouse oocytes. This keratin pro- to Antigenic Challenge with Either
moter resulted in the selective expression of soluble 2C11 or Ovalbumin
CTLA-4Ig in basal squamous epithelial cells most promi- Previous studies of the CD282/2 C57BL/6 mice had dem-
nently in the skin (Vassar and Fuchs, 1991). Founder onstrated that the T cells isolated from the CD28-defi-
mouse number 7 was chosen for the experiments, as cient mice were hyporesponsive in vitro. They re-
offspring from this founder expressed between 10–30 sponded poorly to anti-CD3 cross-linking or stimulation
mg/ml CTLA-4Ig in their sera. CTLA-4Ig Tg mice were with alloantigen. Furthermore, the T cells produced sig-
then backcrossed for three generations to the NOD nificantly reduced amounts of IL-2 in response to mito-
mouse strain, creating an animal in which the CD28/B7 gen (Shahinian et al., 1993; Green et al., 1994). We there-
signaling pathway would bedisrupted during theearliest fore did not anticipate that the CD282/2 NOD mice would
stages of disease development. As seen in Figure 1, develop diabetes at an accelerated rate. Thus, T cells
8.3% of the Tg2 NOD (Non Tg) mice developed diabetes isolated from CD282/2 NOD mice were examined for T
by 24 weeks of age. The low incidence of diabetes was cell function in vivo and in vitro. As seen in Figure 3A,
expected, because not all of the NOD susceptibility T cells isolated from CD282/2 NOD mice proliferated
genes have been fixed by the third backcross genera- poorly following anti-CD3 mAb stimulation as compared
tion. However, amongthe animals expressing the murine with the T cells of the CD281/1 NOD or CD281/2 NOD
CTLA-4Ig transgene (CTLA-4Ig Tg), 100% were hyper- mice. Furthermore, the T cell proliferative responses of
glycemic by 15 weeks of age, including both female and these mice following in vivo immunization with oval-
male mice (Figure 1). Therefore, the blockade of the bumin (OVA) were examined. CD281/2 and CD282/2 NOD
CD28/B7 costimulatory pathway from birth was not only mice were injected in the footpads with 100 mg of oval-
incapable of protecting the NOD mice from diabetes, bumin in complete Freund’s adjuvant (CFA). The drain-
ing lymph node T cells were restimulated with variousbut actually accelerated the disease process.
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Figure 2. Increased Onset and Incidence of
Diabetes in CD282/2 NOD Mice
CD282/2 mice were bred onto the NOD back-
ground for four generations as described in
the Experimental Procedures. Beginning at
10 weeks of age, blood glucose levels of fe-
male (left) and male (right) mice were checked
weekly. CD281/1 mice are represented by
open circles (male: n 5 16), CD281/2 mice by
open squares (male: n 5 32; female: n 5 11),
and CD282/2 by solid circles (male: n 5 21;
female: n 5 12).
doses of OVA in vitro 1 week later. As seen in Figure background. We also examined the amount of IL-2 pro-
duced by the T cells from the various animals following3B, the response of the CD281/2 NOD mice challenged
with OVA was substantially greater than that of the stimulation with either anti-CD3 mAb or OVA. As seen
in Figure 3C, the amount of IL-2 produced by the CD282/2CD282/2 NOD mice. In fact, the T cells from the CD282/2
NOD mice did not proliferate to OVA significantly above NOD T cells to anti-CD3 mAb or to OVA was significantly
Figure 3. T Cells from the CD282/2 NOD Mice
Respond to the Autoantigen GAD, but Do Not
Respond to Physiological Antigen Challenge
(A) Proliferation to anti-CD3 mAb [145-2C11]
was measured following stimulation of
splenic T cells isolated from 10 week old
CD281/1 (solid circles), CD281/2 (solid
squares), or CD282/2 (solid diamonds) NOD
mice for 48 hr with soluble mAb in the pres-
ence of Fc receptor–positive antigen-pre-
senting cells.
(B) Proliferation to OVA was measured using
lymph node cells isolated from CD281/2 NOD
mice (solid squares) and CD282/2 NOD mice
(solid triangles) that had been immunized in
vivo 7 days previously.
(C) Splenic T cells from CD281/1 (solid bars),
CD281/2 (shaded bars), or CD282/2 (cross-
hatched bars)NOD mice were stimulated with
either anti-CD3 (10 mg/ml), OVA (100 mg/ml),
or GAD65 (10 mg/ml). Supernatants were col-
lected at 24 hr and analyzedfor IL-2 by ELISA.
The results presented are the average of 2–4
mice per group and are representative of
three independent experiments. NT, not
tested.
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reduced as compared with the CD28-expressing NOD
mice. These results support previous studies demon-
strating an intrinsic defect in the ability of CD282/2 T
cells to respond to nominal antigen.
T cells from diabetic NOD mice have been shown to
respond toa numberof autoantigens, including glutamic
acid decarboxylase (GAD). This response is vigorous
and selectively present in the autoimmune setting.
Therefore, we next examined the ability of the CD282/2
NOD mice to respond to GAD. In contrast with the gen-
eral immune responses of these mice, T cells isolated
from the CD282/2 NOD mice produced high levels of
IL-2 following challenge with GAD65 (Tisch et al., 1993),
equivalent to the levels produced by the CD281/2 or
CD281/1 NOD T cells. These results suggest that GAD-
specific T cells can develop in these mice in the absence
of CD28 costimulation. Therefore, while the CD282/2
NOD mice were not able to mount a normal immune
response following immunization with antigen or after
T cell receptor cross-linking with anti-CD3 mAbs, they
could respond to a known autoantigen, GAD.
T Cells from CD282/2 NOD Mice Demonstrate
an Imbalanced Th1/Th2 Response
The fact that the T cells isolated from the CD282/2 NOD
Figure 4. Expression of IFNg and IL-4 mRNA by Intrapancreatic
mice were able to produce normal levels of IL-2 in re- Cells Isolated from CD282/2 and CD281/2 NOD Mice
sponse to GAD may explain why these animals still de-
Intrapancreatic cells were isolated from 8-week-old normoglycemic
velop diabetes, but not why the disease occurs with CD282/2 NOD mice (KO) and CD281/2 NOD mice (Htz) from the same
increased penetrance and severity. One possible expla- backcross generation as described in Experimental Procedures.
RNA and cDNA were prepared, and equivalent amounts of cDNAnation comes from recent observations that pathogenic
(based on analysis of HPRT) were used for competitive RT–PCRautoimmune responses frequently involve an imbalance
studies of IFNg and IL-4 gene expression as described (Reiner etin the development of Th1 versus Th2 immune re-
al., 1993). C, competitor, W, wild-type products. The size of the PCRsponses (Katz et al., 1993; Shehadeh et al., 1993; Kuch-
products were as follows: IFNg: C 5 300 amino acids, W 5 234
roo et al., 1995). To examine this possibility, the mRNA amino acids; IL-4: C 5 360 amino acids, W 5 240 amino acids;
levels of IL-4 and interferon-g (IFNg) produced by T cells HPRT: C 5 450 amino acids, W 5 352 amino acids. This result is
representative of two independent experiments.infiltrating the pancreases of CD282/2 NOD (KO) and
CD281/2 NOD (Htz) mice were analyzed by competitive
reverse transcription–polymerase chain reaction (RT–
PCR). The RT–PCR method employed uses a plasmid converse was observed when the Th1 cytokine, IFNg
was analyzed. T cells from the CD282/2 NOD mice re-construct that can compete with cDNA produced from
endogenous mRNA to allow a more quantitative assess- peatedly produced more IFNg than T cells isolated from
bothCD281/1 NOD and CD281/2 NOD mice. In one experi-ment of the cytokines produced by a given T cell popula-
tion (Reiner et al., 1993). As seen in Figure 4, T cells ment, the CD282/2 NOD mice made nearly four times
more IFNg than the CD281/2 NOD mice (Figure 5, upper).from CD281/2 NOD mice appeared to produced more
IL-4 mRNA than the CD282/2 NOD mice, since no com- Thus, the results from these different analyses (RT–PCR
and in vitro cytokine production) suggest that CD282/2petitor was amplified in T cells isolated from the hetero-
zygote animals. In contrast, the CD282/2 NOD mice pro- NOD mice are selectively deficient in their ability to de-
velop or amplify (or both) a Th2-type T cell response,duced dramatically increased amounts of IFNg mRNA
as compared with the CD281/2 NOD mice based on the and may shift their T cell subset development toward a
Th1 phenotype.relative amplification of the wild-type versus competitor
band.
The production of cytokines by T cells isolated from Selective Impairment of Anti-GAD Antibodies
of the IgG1 Subclass in CD282/2 NOD MiceCD28 homozygote, CD28 heterozygote, and CD28
knockout NOD mice following priming with GAD and An analysis of the serum levels of GAD-specific antibod-
ies in CD281/2 NOD and CD282/2 NOD mice confirmedrestimulation with anti-CD3 mAbs was directly exam-
ined. Two representative experiments demonstrated that the CD28-deficient animals mounted a reduced Th2
response (Figure 6). While both the CD282/2 NOD andthat animals expressing CD28 produced significantly
higher quantities of the Th2 cytokine, IL-4, following the CD281/2 NOD mice produced similar levels of the
Th1-dependent IgG2a isotype, the serum from CD282/2activation as compared with T cells isolated from the
CD282/2 NOD mice (Figure 5). In fact, in several experi- NOD mice contained significantly less anti-GAD67 anti-
bodies of the Th2-dependent IgG1 isotype as comparedments, the T cells isolated from the CD282/2 NOD mice
were unable to produce any IL-4 (Figure 5, lower). The with serum from the CD281/2 NOD mice (Elliott et al.,
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Figure 6. Isotypic Analysis of Anti-GAD Antibodies Produced in
CD282/2 NOD Mice
Sera from 8–10-week-old CD282/2 NOD mice (cross-hatched bars)
and CD281/2 NOD mice (shaded bars) were collected and analyzed
by ELISA for the presence of anti-GAD67 antibodies of the IgG1 andFigure 5. CD282/2 NOD Mice Produce a Diminished Th2 Response
IgG2a isotypes as described in the Experimental Procedures.Following In Vitro Stimulation
Splenic T cells from CD281/1 (solid bars), CD281/2 (shaded bars), or
CD282/2 (cross2hatched bars) NOD mice were stimulated with finding that T cells from theCD282/2 NOD mice were able
GAD65 and then restimulated with 145-2C11. Supernatants werethen to mount a potent proliferative response and produce
harvested 48 hr later and examined for the presence of IL-4 and
normal levels of IL-2 to one of the identified autoanti-IFNg. Two independent experiments are shown. The results are the
gens, GAD65 (Tisch et al., 1993). Previous studies haveaverage of four mice per groups.
shown that T cells isolated from CD28-deficient mice
are defective in both their proliferative response and
IL-2-producing capabilities when stimulated with non-1994; Tisch et al., 1993; Kaufman et al., 1993). Taken
together, the absence of the CD28 molecule resulted in specific stimuli such as Concanavalin A and anti-CD3
(Shahinian et al., 1993; Green et al., 1994). Similarily,NOD mice that produced a substantially reduced Th2
response when challenged either in vitro or in vivo. Fur- the bulk T cell population in the CD282/2 NOD mice
responded poorly to alloantigen (data not shown) andthermore, the diminished ability to mount a Th2 re-
sponse to antigenic challenge resulted in a stronger Th1 anti-CD3 mAb. In fact, T cells isolated from OVA/CFA
immunized CD282/2 NOD mice demonstrated decreasedresponse in the CD282/2 NOD mice as shown by an
increased level of IFNg in vivo and following GAD stimu- proliferative capacity and IL-2 production following re-
stimulation with OVA in vitro. These results suggest thatlation invitro. Therefore, thedisruption of CD28 signaling
had profound effects on the differentiation and expan- the autoantigen-specific (GAD) T cells can selectively
overcome the absence of CD28/B7 interactions and re-sion of the Th1 and Th2 subsets that influence disease
incidence and progression. spond effectively to the GAD protein. This observation
may reflect either a difference in the intrinsic require-
ments for CD28 engagement in this autoreactive T cellDiscussion
subset or an evolution in the signaling requirements of
this T cell subset perhaps due to an ongoing exposureThe development of autoimmune diseases is the result
of a number of complex and multigenic events. In this to cytokines or autoantigen in vivo. Repeated exposure
to the autoantigen may over time result in the selectionstudy, we demonstrate that the regulation of CD28-
mediated T cell costimulation is one fundamental ele- of a T cell population capable of responding in a costi-
mulation-independent manner. This may be an intrinsicment of the complicated disease process and one po-
tential target for intervention. Previously, we have shown property of all T cells, as shown by previous experiments
that demonstrated that CD28 is not absolutely essentialthat the blockade of CD28/B7 costimulation with exoge-
nous CTLA-4Ig between 5 and 7 weeks of age blocked to mount a response to repetitive antigenic challenge
in vivo (Green et al., 1994; Lucas et al., 1995) or, moredisease progression. In the current study, however, the
disruption of CD28 signaling from birth using either the interestingly, a heightened characteristic of autoreactive
T cells. Alternatively, there may be other costimulatoryCD282/2 NOD mice or the CTLA-4Ig Tg1 NOD mice re-
sulted in an exacerbation of disease. molecules that substitute for CD28 in these animals.
For instance, we have previously shown that the CD43The first striking observation in this study was the
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molecule can function to costimulate T cells in the CD28 is not the only pathway being disrupted in the Tg1
NOD mice. CTLA-4 interactions are also interrupted, andCD282/2 mice (Sperling et al., 1995). Thus, CD43,or some
other costimulatory molecule may act to “rescue” co- may, therefore, contribute to the disease exacerbation.
Recent studies in vitro (Walunas et al., 1994; Kummelstimulation of GAD-specific T cells in these NOD mice.
Further studies will be necessary to distinguish among and Allison, 1995) and in vivo (Kearney et al., 1995; Tivol
et al., 1995; Waterhouse et al., 1995) have shown thatthese possibilities. However, thepotential for an immune
response to bypass an absolute requirement for CD28/ the CTLA-4 molecule is involved directly in the down-
regulation of T cell responses. CTLA-4-deficient miceB7 costimulation poses a potentially important obstacle
to CD28 antagonist therapies. manifest a massive lymphoproliferative disorder, in-
creased numbers of activated T cells, and autoimmune-Further analysis of the CD282/2 NOD mice suggested
that a major contributing factor to the development of like tissue destruction (Tivol et al., 1995; Waterhouse
et al., 1995). Therefore, the loss of CD28-dependentthe disease was their decreased ability to mount a Th2
response. T cells found infiltrating the pancreases of signaling combined with the lack of the CTLA-4-medi-
ated down-regulatory signals may contribute to the in-these mice expressed decreased amounts of IL-4 and
increased amounts of IFNg mRNA as compared with creased disease severity observed in the CTLA-4Ig Tg1
NOD mice.CD281/2 NOD controls. We also found that in vitro stimu-
lation with GAD resulted in decreased production of IL-4. The work presented in this paper suggests that the
CD28 signaling pathway controls the development andFinally, in vivo measurements of anti-GAD antibodies
showed dramatically decreased levels of Th2-depen- progression of autoimmune diabetes in the NOD mouse
by regulating the balance of Th1 and Th2 T cell subsets.dent IgG1 antibody. Taken together, these results sug-
gest that the CD28-deficient NOD mice mount a sub- During the earliest phases of the disease, the disruption
of CD28/B7-mediated costimulation (CD282/2 NOD andstantially reduced Th2 response. The importance of this
observation is shown by recent animal studies demon- CTLA-4Ig Tg1 NOD mice) resulted in an increased rate
of disease onset. However, these results differ from ourstrating that the genes that control the differentiation of
the Th1/Th2 T cell subsets have an important impact on previous studies in which treatment with CTLA-4Ig
blocked the development of diabetes. While CTLA-4Iginfectious and autoimmune disease progression (Kuch-
roo et al., 1995; Corry et al., 1994). In fact, severalstudies treatment could prevent disease in the NOD mouse, the
timing of this treatment was critical.Only animals treatedhave correlated the development of diabetes in the NOD
mouse model with the balance of a Th1 or Th2 response. between 5 and 7 weeks of age were protected. Thus,
this autoimmune model can be envisioned as a two-The administration of anti-IFNg mAbs blocked the devel-
opment of diabetes in the NOD mouse, while prediabetic stage process. During the early phase of the T cell acti-
vation, T helper cell precursors differentiate into eitherNOD mice wereprotected from disease following admin-
istration of rIL-4 (Debray-Sachs et al., 1991; Rapoport IFNg-producing Th1 or IL-4-producing Th2 subsets. This
“differentiation” stage of disease leads to a stable ratioet al., 1993). IL-12, which promoted the development of
Th1 cells, accelerated disease in NOD mice (Trembleau of Th1:Th2 T cells. Our results suggest that the blockade
of CD28/B7 during the early phase preferentially blockset al., 1995). There is also a correlation of the type of
cellular infiltrate with the lymphokines being produced; Th2 differentiation and contributes to an increased inci-
dence of disease. It appears that the disruption of theIL-4-secreting cells exist as a nondestructive peri-insu-
litis, while IFNg-secreting cells infiltrate the islet and CD28 signaling pathway must occur very early (within
the first 2 weeks), since the treatment of NOD mice withcause b cell destruction (Shehadeh et al., 1993). Finally,
Katz and colleagues demonstrated that the adoptive exogenous CTLA-4Ig at 2–5 weeks of age had no effect
on the development of diabetes (data not shown). Thesetransfer of Th1 clones, derived from a diabetogenic T
cell receptor transgenic mouse, into neonatal NOD mice results agree with previous studies demonstrating that
the differentiation of Th precursors into the Th2 subset,induced diabetes (Katz et al., 1995). Taken together,
these observations indicate that the development of a but not the Th1 subset, is dependent upon CD28 signal-
ing (van der Pauw-Kraan et al., 1993; Seder et al., 1994;dominant Th1 response in the NOD mouse contributes
to the autoimmune process. Therefore, the ability of the Webb and Feldmann, 1995). In addition, this model is
supported by previous studies in CTLA-4Ig Tg mice thatT cells in the CD282/2 NOD mice to mount an effective
autoantigen response of the Th1 but not the Th2 pheno- have been shown to have a reduced Th2 response when
challenged with foreign antigens (Lane et al., 1994;type undoubtably contributes to disease progression.
In this study, both the CD282/2 NOD mice and the Ronchese et al., 1994). Furthermore, it explains the ob-
servation that in the murine model for LeishmaniasisCTLA-4Ig-expressing Tg NOD mice developed disease
at an accelerated rate as compared with their control major, treatment with CTLA-4Ig at the timeof inoculation
protected normally susceptible Th2-producing BALB/clittermates. Since in both cases signaling through CD28
is being inhibited, the mechanisms of disease enhance- mice by reducing the amount of IL-4 being produced
(Corry et al., 1994).ment may be similar. Alternatively, the disease exacer-
bation observed in the CTLA-4Ig Tg1 NOD mice could The ability of exogenous CTLA-4Ig to block autoim-
mune diabetes when administered between 5 and 7be via another mechanism. The CTLA-4Ig Tg1 mice de-
veloped disease as early as the second generation of weeks of age suggests that the CD28 molecule plays a
different role during the second phase. CD28 may bebackcrosses and appeared to have a higher percentage
of animals developing diabetes than did the CD282/2 more critical for the expansion of the autoreactive cells;
thus, blocking this signal may prevent the progressionNOD mice (data not shown), suggesting that disease
may be more severe in the CTLA-4Ig Tg1 NOD mice. of the autoimmune disease. Alternatively, the blockade
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offspring (Shahinian et al., 1993). This F1 generation was back-of CD28/B7 interactions in the differentiated Th1 and
crossed to a NOD mouse. After four rounds of CD28 heterozygousTh2 T cell may selectively inhibit the Th1 subset, which
mice (CD281/2) backcrossing to NOD mice, CD28 heterozygous off-has been shown to cause autoimmune disease or in-
springs were intercrossed to produce CD282/2 NOD, CD281/2 NOD,
crease the protective Th2 subset. In support of this hy- and CD281/1 NOD mice. At each generation, the CD28 genotype
pothesis, in vitro data has shown that, once established, was determined by PCR of genomic tail DNA using primers specific
for either the CD28 gene or the knockout cassette. The PCR wasthe expansion of the Th1 subset is selectivelydependent
performed using Taq polymerase (Boehringer-Mannheim) and eitheron CD28/B7 interactions and more susceptible to the
primers specific for the CD28 gene (a 59 oligonucleotide primerinduction of anergy (Webb and Feldmann, 1995;
of CD28 [CAGTCGCCCCTGCTTGTGGTAGATAGC] paired with a 39McKnight et al., 1994; Harding et al., 1992; Shahinian et
oligonucleotide primer of CD28 [AGTTCCATTGCTCCTCTCGTT
al., 1993). Further analysis is necessary to differentiate GTC]) orprimers specific for the knockout cassette (a 59 oligonucleo-
between these possibilities. tide primer of Neo [ACATTCCAGGCCTGGTGGA] paired with the 39
oligonucleotide primer of CD28 [see above]). Denaturation, anneal-In conclusion, the use of CD28 antagonists to regulate
ing, and extension reactions were carried out at 948C for 15 s, 568Cautoimmune diseases may result in distinct outcomes
for 15 s, and 728C for 30 s, respectively, for 45 cycles and 1 cycledepending on the stage of disease, relative expression
of extension at 728C for 1 min. The screening results were confirmedof the CD28 ligands, and the genetic predisposition to-
by flow cytometric analysis of CD28 expression using a CD28-spe-
ward Th1 and Th2 subsets. Thus, careful manipulation cific mAb, PV-1 (Abe et al., 1995).
of the CD28/B7 signaling pathway will be necessary
to impact reliably upon the course of an autoimmune PCR Screen for Diabetes Susceptibility Genes
disease. Selected CD282/2 NOD mice were screened for several diabetes
susceptibility genes: MHC, D3Mit5, and D3Nds7 (Wickeret al., 1995).
For D3Mit5 andD3Nds7, the PCR was performedusing Taq polymer-Experimental Procedures
ase and primers specific for D3Mit5 (59-AGCCCCTTCCAAGTGTC
TCT) and (39-GGTTTCGGAATGAGATGAGC) or primers specific forMice
NOD and BALB/c mice were purchased from The Jackson Labora- D3Nds7 (59-TGCTCCTCACCAGTCATGC) and (39-TAGTGTTTGC
CAT GGCTCTC). The reactions were carried out at a Mg11 concen-tory (Bar Harbor, ME) and maintained in a pathogen-free animals
facility at the University of Chicago. tration of 1.0 mM. Denaturation, annealing, and extension reactions
were carried out at 948C for 60 s, 558C for 60 s, and 728C for 30 s,
respectively, for 35 cycles. The bands were resolved on a 4% aga-Antibodies and Recombinant Proteins
Human CTLA-4Ig was provided by Repligen Corporation (Cam- rose gel. For the D3Mit5, the NOD allele runs slower (188 bp) than
the B6 allele (182 bp), while in the D3Nds7, the NOD allele runsbridge, MA) (Lenschow et al., 1995). Anti-CD3 mAb (145-2C11) was
produced as previously described (Leo et al., 1987) and purified by faster (118 bp) than the B6 allele (120 bp). For the MHC genes, the
PCR reaction was carried out with the following primers specific forpassage over a protein A–coupled sepharose column. The cDNA
for GAD65 was provided by the laboratory of H. McDevitt (Stanford the second exon of the I-A b chain gene (59-TGTCTTTTCTGTCACCC
TAGAACA) and (39-GAGAAG TCCGACCCTACGACGTGT). The reac-University) and purified GAD65 was prepared as described (Tisch et
al., 1993). tions were carried out at a Mg21 concentration of 4.0 mM. Denatur-
ation, annealing, and extension reactions were carried out at 948C
for 30 s, 668C for 45 s, and 728C for 90 s, respectively, for 40 cycles.Generation and Screening of the CTLA-4Ig Tg NOD Mice
The full length cDNA of the murine CTLA-4Ig gene was cloned into This reaction was then digested with Msp1. The NOD allele will not
cut with Msp1 and will yield a fragment of 282 bp. The B6 allelethe K14/HGH transgenic construct (Vassar and Fuchs, 1991). The
use of the keratin promoter resulted in the generation of founder will yield two fragments of 149 and 133 bp after digestion. These
fragments were resolved on a 4% agarose gel.mice that selectively expressed soluble mCTLA-4Ig in basal squa-
mous epithelial cells, most prominently of the skin, beginning at
9–11 days of gestation. These mice demonstrated normal T cell Assessment of Diabetes
development and proliferative responses in vitro (J. Smith, D. J. L., Starting at 7 weeks of age, the development of diabetes was as-
and J. A. B., unpublished data). The CTLA-4Ig Tg founder mouse sessed by weekly blood glucose measurements using a Lifescan
number 7 was bred to a NOD mouse. Transgene positive F1 offspring glucose meter (One Touch II; Lifescan, Inc., Milpitas, CA). Glucose
were backcrossed to a NOD mouse. This was continued until the strips were provided by Lifescan Inc. Animals were considered dia-
fourth generation, when CTLA-4Ig Tg1 mice began to develop diabe- betic after two consecutive measurements >250 mg/dl. The onset
tes. Screening of each generation was performed as follows. of diabetes was dated from the first of the sequential dates.
Screening for the transgene was performed by PCR of genomic tail
DNA. The PCR was performed using Taq polymerase (Boehringer-
Stimulation AssaysMannheim) and primers specific for the K14 promoter (a 59 oligonu-
Spleen cells isolated from NOD, BALB/c, or CD282/2 NOD mice werecleotide primer [CACGATACACCTGACTAGCTGGGTG] paired with
cultured at 1 3 106 spleen cells/well (24 well plates) in 1 ml ofa 39 oligonucleotide primer [CATCACCCACAGGCTAGCGCCAACT]).
complete media with 5 mg/ml GAD and 20 U/ml rIL-2 at 378C for 7Denaturation, annealing, and extension reactions were carried out
days. At 48 hr, 300 ml of supernatant was removed from each wellat 948C for 15 s, 568C for 15 s, and 728C for 30 s, respectively, for
to analyze cytokine profiles in response to primary stimulations.45 cycles and 1 cycle of extension at 728C for 1 min. Animals that
After 7 days, the cells were subjected to Ficoll/Hypaque gradientwere positive by PCR analysis were then confirmed to be expressing
centrifugation, washed, and replated (3–4 3 105 cells/well) on 24the CTLA-4Ig transgene by serum analysis. Serum was collected
well plates that had been coated with 1 mg/ml 145-2C11. After 48and analyzed for its ability to inhibit binding of FITC-coupled hCTLA-
hr, the supernatants were removed and analyzed for cytokines in4Ig to B7-1 transfected CHO cells as follows. We added 10 ml of
response to the secondary stimulations by ELISA.serum to 1 3 106 B7-1 transfected CHO cells. After 10 min, FITC-
coupled hCTLA-4Ig was added. Cells were analyzed by FACS analy-
sis. Serum concentrations of mCTLA-4Ig were determined by com- In Vivo Antigen Challenge
CD282/2 NOD mice and CD281/2 NOD mice were each immunizedparing the amount of inhibition in the serum with a standard curve
of inhibition by purified mCTLA-4Ig at various concentrations. in the footpads with 100 mg of ovalbumin (OVA) in CFA. After 1 week,
draining lymph nodes were removed and single cell suspensions
were prepared. We plated 5 3 105 lymph node cells per well in 96 wellBreeding of the CD282/2 NOD Mice
CD282/2 NOD mice were generated as follows. A homozygous U-bottom plates with varying concentrations of OVA. Supernatants
from 48 hr of stimulation were analyzed for IL-2 production by ELISA.CD282/2 mouse was bred to a NOD mouse to produce heterozygous
Immunity
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Proliferation assays were pulsed at 60 hr with [3H]thymidine for 8 the results at the 1:20 dilution for anti-GAD antibody were very
reproducible (Smith et al., 1992; Elliott et al., 1994).hr and were then harvested.
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